

Regioselective Palladium-Catalyzed Cross-Coupling Reactions of 2,4,7-Trichloroquinazoline

Peter Wipf,* Kara M. George

University of Pittsburgh, Pittsburgh, PA 15260, USA
Fax +1(412)6240787; E-mail: pwipf@pitt.edu

Received 17 December 2009

This paper is dedicated to Prof. Gerry Pattenden on the occasion of his 70th birthday.

Abstract: The regioselective palladium-catalyzed cross-coupling reactions of 2,4,7-trichloroquinazoline with various aryl- and heteroarylboronic acids are reported. An efficient, sequential strategy was developed that provides access to novel, functionalized heterocycles.

Key words: palladium catalysis, cross-coupling, heterocycles, regioselectivity, quinazoline

Palladium-catalyzed cross-coupling reactions represent a powerful method for the formation of highly substituted heterocycles.¹ The regioselective activation of polyhalogenated heteroaromatics in such reactions has been extensively studied² and can provide a versatile means for the synthesis of libraries containing functionalized substituents in specific positions of the heterocyclic scaffold. The quinazoline moiety is of particular importance, as it is a component of a variety of biologically active compounds, including potent tyrosine kinase inhibitors,³ antibacterial,⁴ and anticancer agents.⁵ For example, trisubstituted quinazoline derivatives such as **A** and **B** have been prepared as part of a series of liver X receptor (LXR) modulators (Figure 1).⁶




Figure 1 Quinazoline derivatives designed as LXR modulators


Quinazolines are also components of several approved drugs, including erlotinib,⁷ used to treat several types of tumors, ivermectin,⁸ an epidermal growth factor receptor inhibitor approved for the treatment of non-small cell lung cancer, and prazosin,⁹ an α -adrenergic receptor blocker.

While the regioselectivity for palladium-catalyzed alkylation,¹⁰ alkynylation,¹¹ and arylation¹² of 2,4-dichloroquinazolines has been previously explored, only the alkylation¹⁰ and alkynylation¹¹ of 6-bromo-2,4-dichloro-

quinazoline have been reported. For cross-coupling reactions employing 2,4-dichloroquinazoline, exclusive selectivity for the most electrophilic C-4 position¹³ has been observed. Attempts to achieve monosubstitution with the more highly halogenated 6-bromo-2,4-dichloroquinazoline resulted in coupling at both the C-4 and C-6 positions in a ratio of 3:1, respectively. To our knowledge, a regioselective method for the sequential polyarylation of trihalogenated quinazolines has not been disclosed. Herein, we describe a versatile new protocol for the regioselective palladium-catalyzed cross-coupling reactions of 2,4,7-trichloroquinazoline¹⁴ with aryl- and heteroarylboronic acids.

Initially, we set out to achieve the regioselective cross-coupling of 2,4,7-trichloroquinazoline by consecutive, Suzuki cross-couplings (Scheme 1, route A). We envisioned the first coupling to take place at the most electrophilic C-4 position, followed by substitutions at the C-2 and C-7 positions, respectively. However, coupling at C-4 proved to be low-yielding due to competitive hydrolysis at that site under the reaction conditions. In order to circumvent this problem, a new route was designed in which the C-4 position was first temporarily deactivated by a thioether, followed by a regioselective cross-coupling at C-2 (Scheme 1, route B). The C-4 position would then be functionalized via a palladium-catalyzed, copper(I)-mediated cross-coupling to provide compounds of type **3**, which could undergo a Suzuki reaction to provide trifunctionalized quinazoline target compounds **4**.

Thioether **1** was readily accessed by treatment of 2,4,7-trichloroquinazoline with 1.05 equivalents of isopropyl mercaptan and NaH. Substitution occurred exclusively at the electrophilic C-4 position. Subsequent regioselective C-2 arylation of **1** proceeded in excellent yields with most arylboronic acids in the presence of 5 mol% Pd(OAc)₂ and 15 mol% Ph₃P at 75 °C, furnishing diaryl products **2** (Table 1, entries 1–8).¹⁵ In the case of oxygen- and nitrogen-containing heterocyclic nucleophiles, slightly lower yields were obtained, presumably due to the decreased reactivity of these reagents,¹⁶ as shown by the need for prolonged reaction times (Table 1, entries 8–10). Excess boronic acid (1.5 equiv) was necessary for complete consumption of starting materials, and attempts to use stoichiometric amounts resulted in incomplete conversions. In addition, efforts to decrease the reaction time by increas-



Scheme 1 Selective cross-coupling strategies to minimize synthetic steps and maximize diversity in quinazolines **4**

ing reaction temperatures resulted in poor regioselectivity and low overall yields.

Stage 2 functionalization at the C-4 position was performed using the palladium-catalyzed, copper(I)-mediated desulfative coupling conditions reported by Liebeskind and coworkers.¹⁷ These reactions were carried out in the presence of excess copper(I) thiophene-2-carboxylate (CuTC) and boronic acid. All desulfative arylations were achieved in excellent yields and complete selectivity for the C-4 position (Table 2).

The third and final cross-coupling reaction was initially carried out using the conditions reported in Table 1. In all cases, incomplete consumption of starting material resulted, even upon heating to reflux and increasing the equivalents of boronic acid. Finally, in order to ensure the complete consumption of starting material, 10 mol% Pd(OAc)₂, 30 mol% Ph₃P, and 4.0 equivalents of boronic acid were used. These conditions resulted in a successful cross-coupling at position C-7 in good yields for both aryl- and heteroarylboronic acids (Table 3).

In conclusion, we have demonstrated that temporary deactivation of the C-4 position by substitution of the chlorine atom with isopropyl mercaptan allows for the subsequent regioselective palladium-catalyzed cross-coupling at the C-2 position in 2,7-dichloroquinazoline **1**. Furthermore, palladium-catalyzed, copper(I)-mediated desulfative coupling at the C-4 position, followed by the final palladium-catalyzed cross-coupling at the C-7 position, provides convenient access to the desired tricarbo-substituted quinazolines. This simple and efficient sequential coupling route to highly substituted quinazolines enables the orchestration of regioselective palladium-catalyzed cross-coupling reactions for the preparation of focused libraries of kinase inhibitors.¹⁸

2,7-Dichloro-4-(isopropylthio)quinazoline (**1**)

To a solution of 2,4,7-trichloroquinazoline¹⁴ (0.300 g, 1.28 mmol) in freshly distilled and degassed THF (13.0 mL) cooled to 0 °C was added a premixed solution of *i*-PrSH (0.12 mL, 1.28 mmol) and NaH (0.032 g, 1.35 mmol) in THF (2.0 mL) dropwise. The mixture was stirred for 16 h, warmed to r.t., poured into ice cold H₂O, ex-

tracted with EtOAc (5 × 25 mL), and washed with H₂O. The combined organic extracts were dried (MgSO₄) and concentrated to give a light yellow residue. The residue was purified by chromatography on SiO₂ (1:50, EtOAc–hexanes) to provide **1** (0.291 g, 83%) as a light yellow crystalline solid; mp 89.1–90.1 °C (EtOAc). IR (ATR): 3075, 2965, 2881, 1551, 1459, 1321, 1224, 1133, 852 cm⁻¹. ¹H NMR (300 MHz, DMSO-*d*₆): δ = 8.07 (d, 1 H, *J* = 9.0 Hz), 7.98 (d, 1 H, *J* = 2.1 Hz), 7.72 (dd, 1 H, *J* = 9.0, 2.1 Hz), 4.18 (sept, 1 H, *J* = 6.9 Hz), 1.46 (d, 6 H, *J* = 6.9 Hz). ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 174.8, 156.0, 149.7, 140.1, 128.9, 126.6, 125.9, 120.2, 36.0, 22.2 (2 C). MS (EI): *m/z* (%) = 272 (33) [M]⁺, 230 (100), 195 (48), 161 (37). HRMS (EI): *m/z* calcd for C₁₁H₁₀Cl₂N₂S: 271.9942; found: 271.9946.

General Procedure for Compounds of Type 2

To a reaction vial was added **1** (1.0 equiv), Pd(OAc)₂ (0.05 equiv), Ph₃P (0.15 equiv), Na₂CO₃ (3.1 equiv), and R¹B(OH)₂ (1.5 equiv). The reaction mixture was flushed with N₂. Freshly distilled and degassed DME and H₂O (DME–H₂O, 10:1) were added via syringe to generate a 0.1 M solution of **1**, and the reaction mixture was stirred at 75 °C under a N₂ atmosphere for the required time. H₂O was added, and the mixture was extracted with CH₂Cl₂. The combined organic layers were washed with brine, dried (MgSO₄), and concentrated under reduced pressure. The crude residue was purified by chromatography on SiO₂ (EtOAc–hexanes or THF–toluene) to give the desired products of type **2**.

7-Chloro-4-(isopropylthio)-2-(thiophen-2-yl)quinazoline (Table 1, Entry 1)

Mp 122.7–124.7 °C (DMSO). IR (ATR): 2973, 2917, 2855, 1524, 1437, 1327, 1236, 988, 837, 773, 714 cm⁻¹. ¹H NMR (300 MHz, DMSO-*d*₆): δ = 8.06 (dd, 1 H, *J* = 3.6, 1.2 Hz), 8.00 (d, 1 H, *J* = 8.7 Hz), 7.95 (d, 1 H, *J* = 2.1 Hz), 7.84 (dd, 1 H, *J* = 5.1, 1.5 Hz), 7.61 (dd, 1 H, *J* = 9.0, 2.1 Hz), 7.26 (dd, 1 H, *J* = 4.8, 3.6 Hz), 4.30 (sept, 1 H, *J* = 6.9 Hz), 1.53 (d, 6 H, *J* = 6.9 Hz). ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 171.2, 156.0, 149.0, 142.8, 139.2, 131.7, 129.8, 128.8, 127.6, 127.0, 125.8, 120.0, 35.7, 22.4 (2 C). ESI-MS: *m/z* (%) = 321 ([M + 1]⁺ 100), 277 (65). ESI-HRMS: *m/z* calcd for C₁₅H₁₄ClN₂S₂ [M + 1]: 321.0287; found: 321.0271.

General Procedure for Compounds of Type 3

To a reaction vial was added a compound of type **2** (1.0 equiv), CuTC (2.2 equiv), and R²B(OH)₂ (2.2 equiv). The reaction mixture was flushed with N₂ and freshly distilled and degassed THF was added via syringe to generate a 0.06 M solution of **2**. The reaction mixture was stirred vigorously at 50 °C under a N₂ atmosphere for the required time. A sat. aq solution of NaHCO₃ was added, and the solution was extracted with CH₂Cl₂. The combined organic layers

were washed with NaHCO_3 , dried (MgSO_4), and concentrated under reduced pressure. The residue was then purified by chromatography on SiO_2 (EtOAc–hexanes or THF–toluene) to provide the corresponding products of type **3**.

7-Chloro-2-phenyl-4-*m*-tolylquinazoline (Table 2, Entry 1)

IR (ATR): 3058, 3030, 2914, 2851, 1556, 1532, 1336, 913, 766, 695, 682 cm^{-1} . ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ = 8.63–8.56 (m, 2 H), 8.22 (d, 1 H, J = 2.1 Hz), 8.11 (d, 1 H, J = 9.0 Hz), 7.73 (dd, 1 H, 9.0, 2.1 Hz), 7.70 (s, 1 H), 7.67 (d, 1 H, J = 7.6 Hz), 7.62–7.57 (m, 3 H), 7.54 (d, 1 H, J = 7.5 Hz), 7.49 (d, 1 H, J = 7.4 Hz), 2.47 (s, 3 H). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$): δ = 168.3, 160.0, 151.9, 139.1, 138.1, 137.1, 136.6, 131.2, 131.0, 130.4, 129.1, 128.8 (2 C), 128.6, 128.4, 128.3 (2 C), 127.3, 127.2, 119.8, 21.1. MS (EI): m/z (%) = 330 (17) $[\text{M}]^+$, 329 (43) $[\text{M} - 1]^+$, 238 (43), 91 (100). HRMS (EI): m/z calcd for $\text{C}_{21}\text{H}_{15}\text{ClN}_2$: 330.0924; found: 330.0930.

General Procedure for Compounds of Type 4

To a reaction vial was added a compound of type **3** (1.0 equiv), $\text{Pd}(\text{OAc})_2$ (0.10 equiv), Ph_3P (0.30 equiv), Na_2CO_3 (6.2 equiv), and

$\text{R}^3\text{B}(\text{OH})_2$ (4.0 equiv). The reaction mixture was flushed with N_2 . Freshly distilled and degassed DME and H_2O (DME– H_2O , 10:1) were added via syringe to generate a 0.1 M solution of **3**, and the reaction mixture was sealed and heated at reflux for the required time. H_2O was added, and the mixture was extracted with CH_2Cl_2 . The combined organic layers were washed with brine, dried (MgSO_4), and concentrated under reduced pressure. The crude residue was purified by chromatography on SiO_2 (EtOAc–hexanes or THF–toluene) to give the desired products of type **4**.

2-(4-*tert*-Butylphenyl)-4-(4-ethylphenyl)-7-(3-methoxyphenyl)-quinazoline (Table 3, Entry 2)

Mp 89.2–91.0 $^\circ\text{C}$ (EtOAc). IR (ATR): 3063, 2959, 2866, 1552, 1528, 1338, 852, 773 cm^{-1} . ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ = 8.55 (d, 2 H, J = 8.6 Hz), 8.37 (d, 1 H, J = 1.7 Hz), 8.18 (d, 1 H, J = 8.7 Hz), 8.03 (dd, 1 H, J = 8.8, 1.8 Hz), 7.86 (d, 2 H, J = 8.1 Hz), 7.61 (d, 2 H, J = 8.6 Hz), 7.52 (d, 2 H, J = 8.2 Hz), 7.51–7.49 (m, 1 H), 7.47 (dd, 2 H, J = 7.1, 1.7 Hz), 7.11–7.03 (m, 1 H), 3.89 (s, 3 H), 2.78 (q, 2 H, J = 7.5 Hz), 1.35 (s, 9 H), 1.30 (t, 3 H, J = 7.6 Hz). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$): δ = 167.6, 159.9, 159.6, 153.6, 151.8,

Table 1 Selective Suzuki Reaction of **1**














			
Entry	R^1	Time (h)	Yield (%)
1		24	99
2		33	92
3		36	90
4		33	95
5		25	93
6		13	89
7		17	89
8		33	79
9		48	66
10		48	53

Table 2 Palladium-Catalyzed, Copper(I)-Mediated Coupling of **2**

Entry	R^1	R^2	Time (h)	Yield (%)
1			26	89
2			22	83
3			19	89
4			19	87
5			19	86
6			27	91
7			13	97
8			48	66

146.3, 145.4, 140.0, 134.9, 134.5, 130.4, 130.1 (2 C), 128.2 (2 C), 128.1 (2 C), 127.6, 126.9, 125.6, 125.5 (2 C), 120.2, 119.7, 114.7, 112.7, 55.3, 34.7, 31.1 (3 C), 28.1, 15.5. MS (EI): m/z (%) = 472 (100) $[M]^+$, 457 (79). HRMS (EI): m/z calcd for $C_{33}H_{32}N_2O$: 472.2515; found: 472.2510.

Supporting Information for this article is available online at <http://www.thieme-connect.com/ejournals/toc/synlett>.

Table 3 Suzuki Reaction of **3**

Entry	R^1	R^2	R^3	Time (h)	Yield (%)
1				34	81
2				22	86
3				34	66

Acknowledgment

We gratefully acknowledge financial support provided by the NIH (P41GM081275).

References and Notes

- (1) Kalinin, V. N. *Synthesis* **1992**, 413.
- (2) Schröter, S.; Stock, C.; Bach, T. *Tetrahedron* **2005**, *61*, 2245.
- (3) (a) Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. *Science* **1994**, *265*, 1093. (b) Uckun, F. M.; Sudbeck, E. A.; Mao, C.; Ghosh, S.; Liu, X.-P.; Vassilev, A. O.; Navara, C. S.; Narla, R. K. *Curr. Cancer Drug Targets* **2001**, *1*, 59. (c) Strawn, L. M.; Shawver, L. K. *Exp. Opin. Invest. Drugs* **1998**, *7*, 553.
- (4) Bedi, P. M. S.; Kumar, V.; Mahajan, M. P. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 5211.
- (5) Foster, B. A.; Coffey, H. A.; Morin, M. J.; Rastinejad, F. *Science* **1999**, *286*, 2507.
- (6) Bernotas, R. C.; Ullrich, J. W.; Travins, J. M.; Wrobel, J. E.; Unwalla, R. J. WO 2009020683 A2, **2009**.
- (7) Gundla, R.; Kazemi, R.; Sanam, R.; Muttineni, R.; Sarma, J. A. R. P.; Dayam, R.; Neamati, N. *J. Med. Chem.* **2008**, *51*, 3367.
- (8) (a) Wakeling, A. E.; Guy, S. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Barker, A. J.; Gibson, K. H. *Cancer Res.* **2002**, *62*, 5749. (b) Baselga, J.; Rischin, D.; Ranson, M.; Calvert, H.; Raymond, E.; Kieback, D. G.; Kaye, S. B.; Gianni, L.; Harris, A.; Bjork, T.; Averbuch, S. D.; Feyereislova, A.; Swaisland, H.; Rojo, F.; Albanell, J. *J. Clin. Oncol.* **2002**, *20*, 4292. (c) Twombly, R. J. *Natl. Cancer Inst.* **2002**, *94*, 1596.
- (9) da Silva, J. F. M.; Walters, M.; Al-Damluji, S.; Ganellin, C. R. *Bioorg. Med. Chem.* **2008**, *16*, 7254.
- (10) (a) Mangalagiu, I.; Benneche, T.; Undheim, K. *Tetrahedron Lett.* **1996**, *37*, 1309. (b) Qingbo, L.; Mangalagiu, I.; Benneche, T.; Undheim, K. *Acta Chem. Scand.* **1997**, *51*, 302.
- (11) Mangalagiu, I.; Benneche, T.; Undheim, K. *Acta Chem. Scand.* **1996**, *50*, 914.
- (12) Charpiot, B.; Brun, J.; Donze, I.; Naef, R.; Stefani, M.; Mueller, T. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 2891.
- (13) (a) Eicher, T.; Hauptmann, S. *The Chemistry of Heterocycles*; Wiley-VCH: Weinheim, **2003**. (b) Garcia, Y.; Schoenebeck, F.; Legault, C. Y.; Merlic, C. A.; Houk, K. N. *J. Am. Chem. Soc.* **2009**, *131*, 6632.
- (14) Curd, H. S.; Landquist, J. K.; Rose, F. L. *J. Chem. Soc.* **1948**, 1759.
- (15) Exclusive coupling at the C-2 position was determined by 2D NMR experiments.
- (16) (a) Barder, T. E.; Walker, S. D.; Martinelli, J. R.; Buchwald, S. L. *J. Am. Chem. Soc.* **2005**, *127*, 4685. (b) Billingsley, K.; Buchwald, S. L. *J. Am. Chem. Soc.* **2007**, *129*, 3358.
- (17) Liebeskind, L. S.; Srogl, J. *Org. Lett.* **2002**, *4*, 979.
- (18) (a) Decornez, H.; Gulyás-Forró, A.; Papp, Á.; Szabó, M.; Sármay, G.; Hajdú, I.; Cseh, S.; Dormán, G.; Kitchen, D. B. *ChemMedChem* **2009**, *4*, 1273. (b) Peng, J.; Lin, W.; Jiang, D.; Yuan, S.; Chen, Y. *J. Comb. Chem.* **2007**, *9*, 431. (c) Wipf, P.; Minion, D. J.; Halter, R. J.; Berggren, M. I.; Ho, C. B.; Chiang, G. G.; Kirkpatrick, L.; Abraham, R.; Powis, G. *Org. Biomol. Chem.* **2004**, *2*, 1911.